{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:07:53Z","timestamp":1775588873863,"version":"3.50.1"},"reference-count":33,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["H0517\/81560132"],"award-info":[{"award-number":["H0517\/81560132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012420","name":"\u201c5511\u201d Innovative Drivers for Talent Teams of Jiangxi Province","doi-asserted-by":"publisher","award":["20165BCB18018"],"award-info":[{"award-number":["20165BCB18018"]}],"id":[{"id":"10.13039\/501100012420","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2020,5,31]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>The present study aims to compare the relative efficacy and safety of different uses of cyclophosphamide (CYC) in lupus nephritis (LN).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>We searched the Cochrane Library, EMBASE, Global Health, MEDLINE and PubMed for articles from the database till June 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>12 randomized controlled trials with 994 participants were included. The meta-analysis indicated that the short-interval lower-dose intravenous CYC regime remarkably reduced 24-hour proteinuria [mean difference (MD) -0.45; 95% confidence interval (CI) -0.62 to -0.27; I2 0%], incidence of major infections [odds ratio (OR) 0.62, 95% CI 0.40 to 0.95; I2 42%], gonadal toxicity (OR 0.41, 95% CI 0.27 to 0.62; I2 0%), and leukopenia (OR 0.55, 95% CI 0.33 to 0.94, I2 0%), while high-dose regime had an obvious lower probability of doubling of serum creatinine (Scr) level (OR 2.43; 95% CI 1.19 to 4.95; I2 0%). However, the difference in the complete and total remission rates between the two regimens was not observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The result suggested that the short-interval lower-dose CYC regime remarkably reduced 24-hour proteinuria and the incidence of adverse events, while the long-course high-dose regime played a significant role in reducing the rate of doubling Scr level.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871530319666191107110420","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T16:56:32Z","timestamp":1573232192000},"page":"687-702","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of Different Uses of Cyclophosphamide in Lupus Nephritis: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9453-0621","authenticated-orcid":true,"given":"Yebei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Nephrology, the Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-6153","authenticated-orcid":true,"given":"Shizhang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the People\u2019s Hospital of Yichun City, Yichun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1740-9358","authenticated-orcid":true,"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1681\/ASN.V102413","volume":"10","author":"Cameron J.S.","year":"1999","unstructured":"Cameron J.S.; Lupus nephritis. J Am Soc Nephrol 1999,10(2),413-424","journal-title":"J Am Soc Nephrol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/IJWH.S28034","volume":"4","author":"Mok C.C.","year":"2012","unstructured":"Mok C.C.; Understanding lupus nephritis: diagnosis, management, and treatment options. Int J Womens Health 2012,4,213-222","journal-title":"Int J Womens Health"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1002\/art.38006","volume":"65","author":"Mok C.C.","year":"2013","unstructured":"Mok C.C.; Kwok R.C.; Yip P.S.; Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2013,65(8),2154-2160","journal-title":"Arthritis Rheum"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00467-004-1553-6","volume":"19","author":"Beimler J.H.","year":"2004","unstructured":"Beimler J.H.; Andrassy K.; Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? Pediatr Nephrol 2004,19(9),949-955","journal-title":"Pediatr Nephrol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"314","author":"Austin H.A.","year":"1986","unstructured":"Austin H.A.; Klippel J.H.; Balow J.E.; le Riche N.G.; Steinberg A.D.; Plotz P.H.; Decker J.L.; Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986,314(10),614-619","journal-title":"N Engl J Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","volume":"125","author":"Gourley M.F.","year":"1996","unstructured":"Gourley M.F.; Austin H.A.; Scott D.; Yarboro C.H.; Vaughan E.M.; Muir J.; Boumpas D.T.; Klippel J.H.; Balow J.E.; Steinberg A.D.; Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996,125(7),549-557","journal-title":"Ann Intern Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","volume":"135","author":"Illei G.G.","year":"2001","unstructured":"Illei G.G.; Austin H.A.; Crane M.; Collins L.; Gourley M.F.; Yarboro C.H.; Vaughan E.M.; Kuroiwa T.; Danning C.L.; Steinberg A.D.; Klippel J.H.; Balow J.E.; Boumpas D.T.; Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001,135(4),248-257","journal-title":"Ann Intern Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/1529-0131(199805)41:5<831:AID-ART9>3.0.CO;2-1","volume":"41","author":"Mok C.C.","year":"1998","unstructured":"Mok C.C.; Lau C.S.; Wong R.W.; Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998,41(5),831-837","journal-title":"Arthritis Rheum"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009408","volume":"96","author":"Tian M.","year":"2017","unstructured":"Tian M.; Song X.; Dong L.; Xin X.; Dong J.; Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis. Medicine (Baltimore) 2017,96(51)","journal-title":"Medicine (Baltimore)"},{"key":"ref=10","volume":"10","author":"Bae S.C. YH L.","year":"2018","unstructured":"Bae S.C. YH L.; Comparative efficacy and safety of low-dose and high-dose cyclophosphamide as induction therapy for lupus nephritis: a network meta-analysis. Z Rheumatol 2018,10","journal-title":"Z Rheumatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"Bertsias G.K.","year":"2012","unstructured":"Bertsias G.K.; Tektonidou M.; Amoura Z.; Aringer M.; Bajema I.; Berden J.H.; Boletis J.; Cervera R.; D\u00f6rner T.; Doria A.; Ferrario F.; Floege J.; Houssiau F.A.; Ioannidis J.P.; Isenberg D.A.; Kallenberg C.G.; Lightstone L.; Marks S.D.; Martini A.; Moroni G.; Neumann I.; Praga M.; Schneider M.; Starra A.; Tesar V.; Vasconcelos C.; van Vollenhoven R.F.; Zakharova H.; Haubitz M.; Gordon C.; Jayne D.; Boumpas D.T.; Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012,71(11),1771-1782","journal-title":"Ann Rheum Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"Higgins J.P.","year":"2003","unstructured":"Higgins J.P.; Thompson S.G.; Deeks J.J.; Altman D.G.; Measuring inconsistency in meta-analyses. BMJ 2003,327(7414),557-560","journal-title":"BMJ"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2288-7-5","volume":"7","author":"Friedrich J.O.","year":"2007","unstructured":"Friedrich J.O.; Adhikari N.K.J.; Beyene J.; Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007,7,5","journal-title":"BMC Med Res Methodol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","volume":"340","author":"Boumpas D.T.","year":"1992","unstructured":"Boumpas D.T.; Austin H.A.; Vaughn E.M.; Klippel J.H.; Steinberg A.D.; Yarboro C.H.; Balow J.E.; Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992,340(8822),741-745","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"Houssiau F.A.","year":"2002","unstructured":"Houssiau F.A.; Vasconcelos C.; D\u2019Cruz D.; Sebastiani G.D.; Garrido Ed Ede.R.; Danieli M.G.; Abramovicz D.; Blockmans D.; Mathieu A.; Direskeneli H.; Galeazzi M.; G\u00fcl A.; Levy Y.; Petera P.; Popovic R.; Petrovic R.; Sinico R.A.; Cattaneo R.; Font J.; Depresseux G.; Cosyns J.P.; Cervera R.; Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002,46(8),2121-2131","journal-title":"Arthritis Rheum"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1002\/art.20666","volume":"50","author":"Houssiau F.A.","year":"2004","unstructured":"Houssiau F.A.; Vasconcelos C.; D\u2019Cruz D.; Sebastiani G.D.; de Ramon Garrido E.; Danieli M.G.; Abramovicz D.; Blockmans D.; Mathieu A.; Direskeneli H.; Galeazzi M.; G\u00fcl A.; Levy Y.; Petera P.; Popovic R.; Petrovic R.; Sinico R.A.; Cattaneo R.; Font J.; Depresseux G.; Cosyns J.P.; Cervera R.; Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004,50(12),3934-3940","journal-title":"Arthritis Rheum"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/ard.2008.102533","volume":"69","author":"Houssiau F.A.","year":"2010","unstructured":"Houssiau F.A.; Vasconcelos C.; D\u2019Cruz D.; Sebastiani G.D.; de Ramon Garrido E.; Danieli M.G.; Abramovicz D.; Blockmans D.; Cauli A.; Direskeneli H.; Galeazzi M.; G\u00fcl A.; Levy Y.; Petera P.; Popovic R.; Petrovic R.; Sinico R.A.; Cattaneo R.; Font J.; Depresseux G.; Cosyns J.P.; Cervera R.; The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010,69(1),61-64","journal-title":"Ann Rheum Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00296-018-3995-3","volume":"38","author":"Mehra S.","year":"2018","unstructured":"Mehra S.; Usdadiya J.B.; Jain V.K.; Misra D.P.; Negi V.S.; Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study. Rheumatol Int 2018,38(4),557-568","journal-title":"Rheumatol Int"},{"key":"ref=19","first-page":"935","volume":"22","author":"Mitwalli A.H.","year":"2011","unstructured":"Mitwalli A.H.; Al Wakeel J.S.; Hurraib S.; Aisha A.; Al Suwaida A.; Alam A.; Hammad D.; Sulimani F.; Memon N.A.; Askar A.; Al Tuwaijri A.; Qudsi A.; Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a long-term randomized controlled trial. Saudi J Kidney Dis Transpl 2011,22(5),935-940","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11255-007-9325-4","volume":"41","author":"Sabry A.","year":"2009","unstructured":"Sabry A.; Abo-Zenah H.; Medhat T.; Sheashaa H.; Mahmoud K.; El-Huseini A.; A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience. Int Urol Nephrol 2009,41(1),153-161","journal-title":"Int Urol Nephrol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/ijn.IJN_2_16","volume":"28","author":"Sahay M.","year":"2018","unstructured":"Sahay M.; Saivani Y.; Ismal K.; Vali P.S.; Mycophenolate versus cyclophosphamide for lupus nephritis. Indian J Nephrol 2018,28(1),35-40","journal-title":"Indian J Nephrol"},{"key":"ref=22","first-page":"21572","volume":"8","author":"Sun J.","year":"2015","unstructured":"Sun J.; Zhang H.; Ji Y.; Gui M.; Yi B.; Wang J.; Jiang J.; Efficacy and safety of cyclophosphamide combined with mycophenolate mofetil for induction treatment of class IV lupus nephritis. Int J Clin Exp Med 2015,8(11),21572-21578","journal-title":"Int J Clin Exp Med"},{"key":"ref=23","first-page":"1005","volume":"118","year":"1993","unstructured":"witte T, Schaumann D, Hein R, et al. Cyclophosphamide bolus therapy in lupus nephritis. Dtsch Med Wochenschr, 1993,118,1005-10","journal-title":"Dtsch Med Wochenschr,"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/ard.2002.003574","volume":"63","author":"Yee C.S.","year":"2004","unstructured":"Yee C.S.; Gordon C.; Dostal C.; Petera P.; Dadoniene J.; Griffiths B.; Rozman B.; Isenberg D.A.; Sturfelt G.; Nived O.; Turney J.H.; Venalis A.; Adu D.; Smolen J.S.; Emery P.; EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004,63(5),525-529","journal-title":"Ann Rheum Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10067-014-2590-6","volume":"33","author":"Zhang X.W.","year":"2014","unstructured":"Zhang X.W.; Li C.; Ma X.X.; Zhao J.X.; An Y.; Liu S.; Li Y.; Li Z.G.; Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study. Clin Rheumatol 2014,33(7),939-945","journal-title":"Clin Rheumatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"Tan E.M.","year":"1982","unstructured":"Tan E.M.; Cohen A.S.; Fries J.F.; Masi A.T.; McShane D.J.; Rothfield N.F.; Schaller J.G.; Talal N.; Winchester R.J.; The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982,25(11),1271-1277","journal-title":"Arthritis Rheum"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"Hochberg M.C.","year":"1997","unstructured":"Hochberg M.C.; Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997,40(9),1725","journal-title":"Arthritis Rheum"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"Hahn B.H.","year":"2012","unstructured":"Hahn B.H.; McMahon M.A.; Wilkinson A.; Wallace W.D.; Daikh D.I.; Fitzgerald J.D.; Karpouzas G.A.; Merrill J.T.; Wallace D.J.; Yazdany J.; Ramsey-Goldman R.; Singh K.; Khalighi M.; Choi S.I.; Gogia M.; Kafaja S.; Kamgar M.; Lau C.; Martin W.J.; Parikh S.; Peng J.; Rastogi A.; Chen W.; Grossman J.M.; American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012,64(6),797-808","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","volume":"15","author":"Weening J.J.","year":"2004","unstructured":"Weening J.J.; D\u2019Agati V.D.; Schwartz M.M.; Seshan S.V.; Alpers C.E.; Appel G.B.; Balow J.E.; Bruijn J.A.; Cook T.; Ferrario F.; Fogo A.B.; Ginzler E.M.; Hebert L.; Hill G.; Hill P.; Jennette J.C.; Kong N.C.; Lesavre P.; Lockshin M.; Looi L.M.; Makino H.; Moura L.A.; Nagata M.; The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004,15(2),241-250","journal-title":"J Am Soc Nephrol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1191\/0961203305lu2060oa","volume":"14","author":"Houssiau F.A.","year":"2005","unstructured":"Houssiau F.A.; Cyclophosphamide in lupus nephritis. Lupus 2005,14(1),53-58","journal-title":"Lupus"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1681\/ASN.2010050472","volume":"21","author":"Bomback A.S.","year":"2010","unstructured":"Bomback A.S.; Appel G.B.; Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010,21(12),2028-2035","journal-title":"J Am Soc Nephrol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1177\/0961203309357763","volume":"19","author":"Lee Y.H.","year":"2010","unstructured":"Lee Y.H.; Woo J.H.; Choi S.J.; Ji J.D.; Song G.G.; Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus 2010,19(6),703-710","journal-title":"Lupus"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/ard.56.8.481","volume":"56","author":"Martin-Suarez I.","year":"1997","unstructured":"Martin-Suarez I.; D\u2019Cruz D.; Mansoor M.; Fernandes A.P.; Khamashta M.A.; Hughes G.R.; Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997,56(8),481-487","journal-title":"Ann Rheum Dis"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/176479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T04:30:45Z","timestamp":1664857845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/176479\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,31]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,31]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530319666191107110420","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}